{
    "doi": "https://doi.org/10.1182/blood-2021-153686",
    "article_title": "Overactivation of the NLRP3 Inflammasome in Chronic Myelomonocytic Leukemia KRAS Mutated Patients Can be Detected By the Apoptosis-Associated Speck-like Protein (ASC) and Reverted By IL1\u03b2 Inhibitors ",
    "article_date": "November 5, 2021",
    "session_type": "636.Myelodysplastic Syndromes-Basic and Translational",
    "abstract_text": "It has been recently shown that RAS mutations, which occur in 11-38% of Chronic Myelomonocytic Leukemia (CMML), do not only act via RAS/MEK/ERK signaling, but contribute to the disease through NLRP3 inflammasome activation (Hamarsheh, Nat Comm 2020). Despite a therapeutic approach based on NLRP3/IL1\u03b2 axis blockade, as bring to a stem cell transplantation (SCT) has been proposed, data on the efficacy of IL1\u03b2 inhibitors in hematopoietic neoplasms is limited. A 55 year old man with previous autoinflammatory episodes (constrictive pericarditis) was diagnosed on September 2020 of CMML-1 KRAS G12D (Inter-2). Due to worsening (orchiepidedymitis, pneumonitis, cellulitis), and the impossibility of performing an SCT at that time, on December 02 2020 he started anakinra (a IL1\u03b2 receptor antagonist) with good response. Due to new episodes of autoinflammation, anakinra was discontinued (12 April 2021) with severe clinical worsening (heart failure) and no response to diuretic/corticosteroid. After anakinra was restarted (04 May 2021), a progressive improvement was seen, allowing a successful pericardiectomy before an SCT. We obtained blood samples from this patient (at different times) and plasma and whole blood samples from 11 and 5 other CMML KRAS mut patients, respectively. We also included CMML patients without KRAS mutations (KRAS wt ) (n=8), with sepsis (n=5) and healthy individuals (n=9). Plasma levels of 15 inflammatory cytokines associated with NLRP3 inflammasome and NFkB pathways were measured using a customized MILLIPLEX \u00ae kit. The inflammasome marker activation assays were conducted as previously published (Mart\u00ednez Garc\u00eda JJ, Nature Comm 2019). Compared to healthy controls, KRAS wt CMML patients did not show differences in any cytokine tested, except IL6, while KRAS mut patients showed significantly higher levels of IL1\u03b1, IL1ra, IL18, IL12p40 (associated with NLRP3 inflammasome), IL6, IL8 (associated with NFkB pathway) and M-CSF (Fig. 1A B). Compared to KRAS wt CMML patients, those with KRAS mut showed higher levels of cytokines associated with both the NLRP3 and NFkB pathways, reaching statistical significance for those related with NLRP3 inflammasome. We also observed changes in inflammasome related cytokines before and after anakinra (Table 1). This cytokine profile in the plasma made us analyze the oligomerization of ASC as a marker of inflammasome activation in monocytes of KRAS mut CMML. We found that in all cases of KRAS mut CMML patients around 30 to 80% of monocytes presented oligomers of ASC measured by the time of flight assay, while in healthy donors and KRAS wt CMML patients, ASC oligomerization occurred upon NLRP3 inflammasome activation with lipopolysaccharide (LPS) + ATP or Pyrin inflammasome activation with LPS and Clostridium difficile B toxin (TcdB) (Fig. 2A). Ex vivo activation of PBMCs from KRAS mut CMML patients showed that despite the high percentage of cells with ASC oligomers, very low levels of IL1b released from these cells, even when NLRP3 was activated with LPS+ATP (Fig. 2B), suggesting that this inflammasome is activated in vivo and could not be further activated ex vivo . As control, Pyrin inflammasome activation in PBMCs from KRAS mut CMML was able to induce IL1b release similarly to healthy controls (Fig. 2B). We then found that anakinra treatment of the KRAS mut CMML patient followed in this study, resulted in a decrease of the percentage of monocytes with basal active inflammasomes (Fig. 2C). A little ex vivo activation of the NLRP3 inflammasome was obtained when cells were treated with LPS+ATP, while Pyrin inflammasome was activated at normal levels after LPS+TcdB treatment (Fig. 2D). The inflammasome basal activation increased in the monocytes of the KRAS mut CMML patient after anakinra withdraw and during clinical deterioration and restarting anakinra (second arrow) decreased the basal percentage of monocytes with ASC oligomers (Fig. 2C). Since ASC oligomers are associated to pyroptosis via caspase 1 activation and gasdermin D processing, we then analyzed pyroptotic markers in the plasma of the patient during the time. ASC was increased when monocytes presented elevated percentage of ASC oligomers (Fig. 2E), suggesting that ASC detection could be a promising biomarker. Overall, we show that, in vivo, the NLRP3 inflammasome activation of KRAS mut CMML patients may revert with IL1\u03b2 blockers. ASC could identify those candidates to receive this therapy. PI18/00316 Figure 1 View large Download slide Figure 1 View large Download slide  Close modal Disclosures Jerez:  Novartis: Consultancy; BMS: Consultancy; GILEAD: Research Funding. Bellosillo:  Thermofisher Scientific: Consultancy, Speakers Bureau; Roche: Research Funding, Speakers Bureau; Qiagen: Consultancy, Speakers Bureau. Hern\u00e1ndez-Rivas:  Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene/BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees. Ferrer Marin:  Cty: Research Funding; Incyte: Consultancy, Research Funding; Novartis: Speakers Bureau.",
    "author_names": [
        "Laura Hurtado-Navarro",
        "Ernesto J Cuenca",
        "Eva Soler",
        "Andres Jerez",
        "Helios Mart\u00ednez-Banaclocha",
        "Esperanza Such",
        "Beatriz Bellosillo",
        "Lurdes Zamora",
        "Jesus Maria Hern\u00e1ndez-Rivas",
        "Javier Marco",
        "Laura Mart\u00ednez-Alarc\u00f3n",
        "Mar\u00eda Dolores Linares-Latorre",
        "Josefa Marco",
        "Sara Garc\u00eda \u00c1vila",
        "Paula Amat",
        "Teresa Gonz\u00e1lez",
        "Marta Mart\u00edn Izquierdo",
        "Montserrat Arnan Sangerman",
        "Helena Pomares",
        "Tzu Hua Chen-Liang",
        "Maite Herranz",
        "Gonzalo Carre\u00f1o",
        "Carlos Garcia-Palenciano",
        "Raul Teruel Montoya",
        "Pablo Pelegrin",
        "Francisca Ferrer Marin"
    ],
    "author_dict_list": [
        {
            "author_name": "Laura Hurtado-Navarro",
            "author_affiliations": [
                "L\u00ednea de Inflamaci\u00f3n Molecular, Instituto Murciano de Investigaci\u00f3n Biosanitaria IMIB-Arrixaca, Hospital Cl\u00ednico Universitario Virgen de la Arrixaca, Murcia, Spain"
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Ernesto J Cuenca",
            "author_affiliations": [
                "CIBER Enfermedades raras CIBER-ER (CB15/00055), Murcia, Spain",
                "Unidad de Hematolog\u00eda y Oncolog\u00eda M\u00e9dica. Hosp. Univ. Morales-Meseguer. Centro Regional de Hemodonaci\u00f3n. Universidad de Murcia. IMIB-Arrixaca, Murcia, Spain"
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Eva Soler",
            "author_affiliations": [
                "Unidad de Hematolog\u00eda y Oncolog\u00eda M\u00e9dica. Hosp. Univ. Morales-Meseguer. Centro Regional de Hemodonaci\u00f3n. Universidad de Murcia. IMIB-Arrixaca, Murcia, Spain"
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Andres Jerez",
            "author_affiliations": [
                "Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos (GESMD), Valencia, Spain",
                "Servicio de Hematolog\u00eda y Oncolog\u00eda M\u00e9dica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonaci\u00f3n, Universidad de Murcia, IMIB, Murcia, Spain"
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Helios Mart\u00ednez-Banaclocha",
            "author_affiliations": [
                "Molecular Inflammation Research Group, Hospital Cl\u00ednico Universitario Virgen de la Arrixaca, IMIB, Murcia, Spain"
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Esperanza Such",
            "author_affiliations": [
                "CIBERONC, Madrid, Spain",
                "Hematology Department., Hospital Universitario y Polit\u00e9cnico La Fe, Valencia, Spain"
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Beatriz Bellosillo",
            "author_affiliations": [
                "Pathology Department-IMIM, Universidad Pompeu Fabra, Hospital del Mar, Barcelona, Barcelona, ESP Group of Applied Clinical Research in Hematology. Cancer research program-IMIM, Barcelona, Spain"
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Lurdes Zamora",
            "author_affiliations": [
                "Hematology Department, ICO - Hospital Germans Trias i Pujol, Badalona, Spain"
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jesus Maria Hern\u00e1ndez-Rivas",
            "author_affiliations": [
                "HARMONY, European Network, Spain",
                "Complejo Asistencial Universitario de Salamanca Hospital Cl\u00ednico, Salamanca, Spain",
                "IBSAL, IBMCC, CIC, Universidad de Salamanca-CSIC, Salamanca, Spain"
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Javier Marco",
            "author_affiliations": [
                "Servicio Hematologia Hospital La Fe, Valencia, Spain"
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Laura Mart\u00ednez-Alarc\u00f3n",
            "author_affiliations": [
                "General Surgery Service, Virgen de la Arrixaca University Hospital, Instituto Murciano de Investigaciones Biosanitarias (IMIB), Murcia, Spain"
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mar\u00eda Dolores Linares-Latorre",
            "author_affiliations": [
                "Departamento de Hematolog\u00eda, Instituto Valenciano de Oncolog\u00eda, Valencia, Spain"
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Josefa Marco",
            "author_affiliations": [
                "Hospital Dr. Peset, Valencia, Spain"
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Sara Garc\u00eda \u00c1vila",
            "author_affiliations": [
                "Servei d'Hematologia Clinica, Hospital del Mar, Barcelona, Spain",
                "Grup de Recerca Cl\u00ednica, Aplicada en Neopl\u00e0sies Hematol\u00f2giques-Hospital del Mar-IMIM. Department of Hematology, Hospital del Mar., Barcelona, Spain",
                "Hematology Department, University Hospital \"Marqu\u00e9s de Valdecilla\", Santander, Spain"
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Paula Amat",
            "author_affiliations": [
                "Hematology Department, Servicio de Hematolog\u00eda, Hospital Cl\u00ednico Universitario de Valencia, Valencia, Spain"
            ],
            "author_rank": 15,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Teresa Gonz\u00e1lez",
            "author_affiliations": [
                "Unidad de Diagn\u00f3stico Molecular y Celular del C\u00e1ncer, Centro de Investigaci\u00f3n del C\u00e1ncer-Universidad de Salamanca (IBMCC, USAL-CSIC); Gen\u00e9tica Molecular en Oncohematolog\u00eda, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), Salamanca, Spain",
                "Servicio de Hematolog\u00eda Cl\u00ednica, Hospital Universitario de Salamanca, Salamanca, Salamanca, Spain",
                "Servicio de Hematolog\u00eda, Hospital Universitario de Salamanca, Salamanca, Spain"
            ],
            "author_rank": 16,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Marta Mart\u00edn Izquierdo",
            "author_affiliations": [
                "Unidad de Diagn\u00f3stico Molecular y Celular del C\u00e1ncer, Centro de Investigaci\u00f3n del C\u00e1ncer-Universidad de Salamanca (IBMCC, USAL-CSIC); Gen\u00e9tica Molecular en Oncohematolog\u00eda, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), Salamanca, Spain"
            ],
            "author_rank": 17,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Montserrat Arnan Sangerman",
            "author_affiliations": [
                "Institut Catal\u00e0 d'Oncologia, Hospital Duran i Reynals, Institut d'Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), Universitat de Barcelona, L Hospitalet De Llobregat (barcelona), Spain"
            ],
            "author_rank": 18,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Helena Pomares",
            "author_affiliations": [
                "Hematology Department., Hospital Duran i Reynals. Institut Catal\u00e0 d'Oncologia, Hospital Duran i Reynals. Institut Catal\u00e0 d'Oncologia, Hospitalet, BARCELONA, Spain"
            ],
            "author_rank": 19,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Tzu Hua Chen-Liang",
            "author_affiliations": [
                "Hematology and Medical Oncology Department, Hospital Morales Meseguer. Centro Regional de Hemodonaci\u00f3n. Universidad de Murcia. IMIB, MURCIA, Murcia, Spain"
            ],
            "author_rank": 20,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Maite Herranz",
            "author_affiliations": [
                "Internal Medicine Service, Hospital Universitario Morales Meseguer, Murcia, Spain"
            ],
            "author_rank": 21,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Gonzalo Carre\u00f1o",
            "author_affiliations": [
                "Hematological Malignancies Clinical Research Unit, CNIO, Madrid, Spain",
                "Hematology Department, Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Sanitaria Imas12, Madrid, Spain"
            ],
            "author_rank": 22,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Carlos Garcia-Palenciano",
            "author_affiliations": [
                "Department of Anesthesiology, Hospital Universitario Virgen De La Arrixaca, Murcia, Spain"
            ],
            "author_rank": 23,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Raul Teruel Montoya",
            "author_affiliations": [
                "CIBER Enfermedades raras CIBER-ER (CB15/00055), Murcia, Spain",
                "Hospital Universitario Morales Meseguer, Centro Regional de Hemodonaci\u00f3n, Universidad de Murcia, IMIB-Arrixaca, Murcia, Spain"
            ],
            "author_rank": 24,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Pablo Pelegrin",
            "author_affiliations": [
                "Univerisity Clinical Hospital Virgen Arrixaca, Murcia, ESP"
            ],
            "author_rank": 25,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Francisca Ferrer Marin",
            "author_affiliations": [
                "Unidad de Hematolog\u00eda y Oncolog\u00eda M\u00e9dica. Hosp. Univ. Morales-Meseguer. Centro Regional de Hemodonaci\u00f3n. Universidad de Murcia. IMIB-Arrixaca, Murcia, Spain",
                "CIBERER (U-765), Murcia, Spain",
                "UCAM, Murcia, Spain"
            ],
            "author_rank": 26,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-06-22T13:04:35",
    "is_scraped": "1"
}